Drug intelligence / Profile preview

Convidecia Air XBB.1.5

Development stage: Preclinical
Lead developer: CanSino Biologics
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Inhalation

Overview

Convidecia Air XBB.1.5 is an inhaled recombinant viral vector vaccine developed by CanSino Biologics for the prevention of COVID-19 caused by the SARS-CoV-2 XBB.1.5 (Omicron) variant. It utilizes a replication-defective Adenovirus Type 5 (Ad5) vector platform to express the SARS-CoV-2 XBB.1.5 variant spike protein. The vaccine is administered via oral inhalation using a nebulizer that converts the liquid formulation into an aerosol, allowing for a needle-free delivery method. This route is specifically designed to induce mucosal immunity in the respiratory tract, in addition to systemic humoral and cellular immune responses, providing a multi-layered defense against infection and transmission of the virus.

Brand names: Convidecia Air XBB.1.5Convidecia Air
Other names: Inhaled Ad5-nCoV XBB.1.5SARS-CoV-2 XBB.1.5 variant (spike) inhalation recombinant vaccine (Adenovirus Type 5 vector)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Convidecia Air XBB.1.5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Convidecia Air XBB.1.5.

Explore the full profile